|
Daily Medical Update
Endometrial cancer
Tuesday, April 21, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Critical reviews in oncology/hematology (2025) - Systematic Review
Key Findings
- Adding immune checkpoint inhibitors to systemic therapy improved progression-free survival (HR 0.71) and overall survival (HR 0.79) versus systemic therapy alone in the intention-to-treat population.
- In dMMR tumors, chemo-immunotherapy produced larger gains in progression-free survival (HR 0.40) and overall survival (HR 0.44), while pMMR disease still showed improved progression-free survival (HR 0.76) without a clear overall survival benefit.
📋 Practice Implication: For advanced or recurrent disease, chemo-immunotherapy should be prioritized when patients are eligible, with the strongest expectation of benefit in dMMR tumors and more measured expectations in pMMR disease.
|
Gynecologic oncology (2025) - Systematic Review
Key Findings
- Preoperative ctDNA positivity was associated with worse progression-free survival, with a hazard ratio of 3.69 for recurrence or progression.
- Postoperative ctDNA positivity carried an even larger adverse signal for progression-free survival (HR 12.61), increasing recurrence risk beyond preoperative testing alone.
📋 Practice Implication: Perioperative ctDNA testing can help identify patients who warrant adjuvant intensification or closer surveillance after definitive surgery.
|
JCO global oncology (2026) - Systematic Review
Key Findings
- L1CAM positivity was associated with worse disease-specific survival (hazard ratio 2.49) and progression-free survival (hazard ratio 2.50) across pooled endometrial cancer cohorts.
- Prevalence was highest in p53abn tumors (52.86%) and MMR-D tumors (52.16%), and the adverse survival effect was especially pronounced in NSMP disease (HR 5.41).
📋 Practice Implication: L1CAM staining can refine postoperative risk stratification, especially in NSMP and MMR-D tumors where adjuvant escalation decisions remain difficult.
|
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026) - Systematic Review
Key Findings
- Adjuvant chemoradiotherapy or radiotherapy improved overall survival versus chemotherapy alone in advanced clear cell endometrial cancer (HR 0.63).
- The pooled estimate corresponds to a 37% reduction in risk of death, with no evidence of meaningful heterogeneity across the included studies.
📋 Practice Implication: For stage III or IV clear cell histology after surgery, radiation-containing adjuvant plans deserve preference over chemotherapy alone when feasible.
|
Irish journal of medical science (2025) - Meta-Analysis
Key Findings
- Targeted therapies did not significantly improve progression-free survival overall, but they reduced adverse effects versus comparison regimens in the pooled analysis.
- Chemotherapy alone did not substantially improve survival rates, while anastrozole and vistusertib showed efficacy signals among the included randomized data.
📋 Practice Implication: This review supports selective use of targeted agents for advanced disease when toxicity reduction matters, but it does not justify broad treatment escalation without biomarker-guided selection.
|
|
💡
Summary
Recent endometrial cancer meta-analyses support a more risk-adapted model of care: chemo-immunotherapy improves outcomes in advanced or recurrent disease, while perioperative ctDNA and L1CAM identify patients with markedly higher recurrence risk who may need stronger adjuvant planning. Histology-specific evidence also favors radiation-containing adjuvant therapy for advanced clear cell tumors, and broader targeted-therapy reviews suggest selective activity with lower toxicity even though pooled survival gains remain inconsistent. Overall, the strongest new literature pushes management toward tighter molecular and minimal-residual-disease stratification rather than uniform treatment escalation.
|
|